Assessment of Superficial Femoral Artery Lesions With FFR From the ACIST Navvus® Catheter (FLO THRU)
Primary Purpose
Peripheral Arterial Disease, Superficial Femoral Artery Stenosis
Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Fractional Flow Reserve (FFR)
High Definition Intravascular Ultrasound (HD-IVUS)
Sponsored by
About this trial
This is an interventional diagnostic trial for Peripheral Arterial Disease
Eligibility Criteria
Inclusion Criteria:
- Age 18-79 at the time of planned SFA intervention
- SFA lesion requires intervention (according to ACC/AHA/SCAI/SIR/SVM 2018 Appropriate Use Criteria for Peripheral Artery Intervention, ABI, imaging, and/or clinical symptoms)
- Index SFA lesion is ≤150 mm
- Rutherford Classification of Peripheral Artery Disease (PAD) is Class 2, 3, 4, or 5
- Minimum two vessel run-off without a hemodynamically significant lesion below the treatment lesion (in at least one vessel to the foot) in the opinion of the treating physician
Exclusion Criteria:
- Study lesion is a Chronic Total Occlusion (CTO)
- Clinically significant (in the opinion of the treating physician) inflow disease of the aorta, common iliac, external iliac, or common femoral artery
- Presence of an additional hemodynamically significant stenosis within the SFA in the opinion of the treating physician
- Active cancer (any type)
- Life expectancy less than 1 year
- Pregnancy
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Other
Arm Label
Main study arm
Sub-study
Arm Description
All subjects will have their SFA lesion assessed with FFR measurement.
Last 50 enrolled subjects will have HD-IVUS in addition to FFR.
Outcomes
Primary Outcome Measures
Post-PVI FFR
Explore the correlation of post-PVI FFR values with other established clinical measures (i.e. 6MWT, ABI, VQ-6, WIQ, and arterial duplex US)
Secondary Outcome Measures
Full Information
NCT ID
NCT05079906
First Posted
October 4, 2021
Last Updated
October 18, 2022
Sponsor
Acist Medical Systems
1. Study Identification
Unique Protocol Identification Number
NCT05079906
Brief Title
Assessment of Superficial Femoral Artery Lesions With FFR From the ACIST Navvus® Catheter
Acronym
FLO THRU
Official Title
Assessment of Superficial Femoral Artery Lesions With FFR From the ACIST Navvus® Catheter
Study Type
Interventional
2. Study Status
Record Verification Date
October 2022
Overall Recruitment Status
Withdrawn
Why Stopped
Withdrawn due to timing
Study Start Date
May 2022 (Anticipated)
Primary Completion Date
June 2024 (Anticipated)
Study Completion Date
June 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Acist Medical Systems
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study is intended to help establish standard procedures for use of FFR in the peripheral arterial system and to evaluate the correlation of post-procedural FFR values and clinical outcomes in Superficial Femoral artery (SFA) interventions in subjects ages 18 to 79 with PAD.
Detailed Description
The ACIST Navvus Rapid Exchange FFR MicroCatheter is a rapid exchange catheter with a pressure sensor located at the distal tip that allows the operator to use their preferred standard 0.014-inch coronary guidewire for peripheral vascular intervention (PVI), eliminating the need for a wire exchange. The fractional flow reserve (FFR) measurements obtained with Navvus represent the degree of stenosis in an artery via comparison of the distal lesion value to the proximal lesion value.
While FFR has evolved as the gold standard for identifying coronary stenoses that may cause myocardial ischemia, it remains underutilized in the diagnosis and treatment of peripheral lesions. FFR cutoff values which could guide PVI decisions are yet to be defined and accepted. Routine use of FFR in patients with peripheral artery disease (PAD) may play an important role in determining the appropriateness of interventions in the peripheral vasculature by introducing a more objective assessment. Shishehbor and Agarwal further highlighted the potential economic benefit of FFR use in peripheral vessels by stating "The Affordable Care Act and higher emphasis on quality rather than quantity should support the use of [IVUS or FFR] to make peripheral interventions more accurate, safer, and better".
This study is intended to help establish standard procedures for use of FFR in the peripheral arterial system and to evaluate the correlation of post-procedural FFR values and clinical outcomes in Superficial Femoral artery (SFA) interventions in subjects ages 18 to 79 with PAD (Rutherford Classification 2, 3, 4, or 5). FFR measurements will be collected using the Navvus catheter pre- and post-PVI. A subset of study subjects will also have post-intervention IVUS imaging performed with the Kodama catheter.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Arterial Disease, Superficial Femoral Artery Stenosis
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Main study arm
Arm Type
Other
Arm Description
All subjects will have their SFA lesion assessed with FFR measurement.
Arm Title
Sub-study
Arm Type
Other
Arm Description
Last 50 enrolled subjects will have HD-IVUS in addition to FFR.
Intervention Type
Device
Intervention Name(s)
Fractional Flow Reserve (FFR)
Intervention Description
Fractional Flow Reserve (FFR) for all enrolled subjects. All interventional procedures, including FFR and HD IVUS, will be conducted in accordance with current approved User Guides and Instructions for Use.
Intervention Type
Device
Intervention Name(s)
High Definition Intravascular Ultrasound (HD-IVUS)
Intervention Description
High Definition Intravascular Ultrasound (HD-IVUS) in addition to FFR for last 50 enrolled subjects. All interventional procedures, including FFR and HD IVUS, will be conducted in accordance with current approved User Guides and Instructions for Use.
Primary Outcome Measure Information:
Title
Post-PVI FFR
Description
Explore the correlation of post-PVI FFR values with other established clinical measures (i.e. 6MWT, ABI, VQ-6, WIQ, and arterial duplex US)
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
79 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 18-79 at the time of planned SFA intervention
SFA lesion requires intervention (according to ACC/AHA/SCAI/SIR/SVM 2018 Appropriate Use Criteria for Peripheral Artery Intervention, ABI, imaging, and/or clinical symptoms)
Index SFA lesion is ≤150 mm
Rutherford Classification of Peripheral Artery Disease (PAD) is Class 2, 3, 4, or 5
Minimum two vessel run-off without a hemodynamically significant lesion below the treatment lesion (in at least one vessel to the foot) in the opinion of the treating physician
Exclusion Criteria:
Study lesion is a Chronic Total Occlusion (CTO)
Clinically significant (in the opinion of the treating physician) inflow disease of the aorta, common iliac, external iliac, or common femoral artery
Presence of an additional hemodynamically significant stenosis within the SFA in the opinion of the treating physician
Active cancer (any type)
Life expectancy less than 1 year
Pregnancy
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Assessment of Superficial Femoral Artery Lesions With FFR From the ACIST Navvus® Catheter
We'll reach out to this number within 24 hrs